Vifor Pharma Acquires Inositec
Summary
Vifor Pharma, a St. Gallen, Switzerland-based is to acquire Inositec AG, a Zurich Switzerland-based developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001. Led by Mattias Ivarsson, Founder and Chief Executive Officer, Inositec is advancing INS-3001, which is being developed in non-dialysis vascular and cardiovascular calcification disorders, such as CKD-associated PAD and Aortic Valve Stenosis (AVS). With INS-3001, Vifor Pharma will further strengthen its nephrology portfolio helping patients suffering from accelerated vascular calcification disorders at all stages of chronic kidney disease (CKD). With INS-3001 daily subcutaneous dosing, patients with earlier stages of vascular calcification can be optimally treated, while end-stage kidney disease patients will benefit from the three times per week dosing regimen of SNF472, a novel, first-in-class inhibitor of vascular calcification in phase-III, developed for the treatment of calcific uremic arteriolopathy (CUA) and Peripheral Artery Disease (PAD) in patients with end-stage kidney disease developed by Sanifit.